DNER and acute myeloid leukemia: Similarly, a phase I study of BET inhibitor mivebresib alone or in combination with venetoclax in 44 patients with relapsed/refractory acute myeloid leukemia revealed higher efficacy in the combination group compared with mivebresib monotherapy.45